IP Library › Granted Patent US 9,630,970

Granted Patent B2

US 9,630,970 · App. 15/097,402 · Granted Apr 25, 2017

TYK2 inhibitors and uses thereof

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,630,970
App. No.: 15/097,402
Filed: Apr 13, 2016
Granted: Apr 25, 2017
Kind: B2
Examiner: RAHMANI, NILOOFAR
Art Unit: 1625
USPC: 514/210.18

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Claims (79)

1. A method of treating a TYK2-mediated disorder, disease, or condition in a patient wherein the disorder, disease, or condition is an autoimmune disorder selected from type 1 diabetes, systemic lupus erythematosus, multiple sclerosis, psoriasis, Crohn's disease, ulcerative colitis, and inflammatory bowel disease, comprising administering to said patient a compound of formula I, or a pharmaceutical composition thereof:

or a pharmaceutically acceptable salt thereof, wherein:

each of X and Y is independently ═C(R 6 )— or ═N—, provided that X and Y are not simultaneously ═C(R 6 )—;

Ring A is phenyl; a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-6 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 4-6 membered saturated or partially unsaturated carbocyclic ring; wherein Ring A is substituted with m instances of R 7 ;

each of R 1 and R 1′ is independently hydrogen, —R 2 , halogen, —CN, —NO 2 , —OR, —SR, —NR 2 , —S(O) 2 R, —S(O) 2 NR 2 , —S(O)R, —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , or —N(R)S(O) 2 R; or

R 1 and R 1′ are taken together with their intervening atoms to form an optionally substituted 3-7 membered spiro-fused ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each R 2 is independently an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur,

R 3 is a group selected from C 1-6 alkyl, phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R 3 is substituted with n instances of R 8 ;

R 4 is hydrogen or optionally substituted C 1-6 aliphatic;

R 5 is a group selected from hydrogen, —R 2 , halogen, —CN, —NO 2 , —OR, —SR, —NR 2 , —S(O) 2 R, —S(O) 2 NR 2 , —S(O)R, —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , —N(R)S(O) 2 R, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R 5 is substituted with p instances of R 9 ;

provided that when R 3 is other than phenyl, R 5 is not hydrogen or unsubstituted alkyl when L 1 is a covalent bond;

each instance of R 6 , R 7 , and R 8 is independently —R 2 , halogen, —CN, —NO 2 , —OR, —SR, —NR 2 , —S(O) 2 R, —S(O) 2 NR 2 , —S(O)R, —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , or —N(R)S(O) 2 R;

each instance of R 9 is independently oxo, C 1-6 hydroxyaliphatic, —R 2 , halogen, —CN, —NO 2 , —OR, —SR, —NR 2 , —S(O) 2 R, —S(O) 2 NR 2 —S(O)R, —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , or —N(R)S(O) 2 R;

L 1 is a covalent bond or a C 1-6 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(O)—, —C(O)N(R)—, —N(R)S(O) 2 —, —S(O) 2 N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —S(O)— or —S(O) 2 —;

m is 0-4;

n is 0-4;

p is 0-6; and

each R is independently hydrogen, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or;

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

2. A method of treating a TYK2-mediated disorder disease, or condition in a patient wherein the disorder, disease, or condition is an inflammatory disorder selected from rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, Crohn's disease, ulcerative colitis, and inflammatory bowel disease, comprising administering to said patient a compound of formula I, or a pharmaceutical composition thereof:

or a pharmaceutically acceptable salt thereof, wherein;

each of X and Y is independently ═C(R 6 )— or ═N—, provided that X and Y are not simultaneously ═C(R 6 )—;

Ring A is phenyl; a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-6 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 4-6 membered saturated or partially unsaturated carbocyclic ring; wherein Ring A is substituted with m instances of R 7 ;

R 4 is hydrogen or optionally substituted C 1-6 aliphatic;

R 5 is a group selected from hydrogen, —R 2 , halogen, —CN, —NO 2 , —OR, —SR, —NR 2 , —S(O) 2 R, —S(O) 2 NR 2 —S(O)R, —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , —N(R)S(O) 2 R, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R 5 is substituted with p instances of R 9 ;

provided that when R 3 is other than phenyl, R 5 is not hydrogen or unsubstituted alkyl when L 1 is a covalent bond;

each instance of R 6 , R 7 , and R 8 is independently —R 2 , halogen, —CN, —NO 2 , —OR, —SR, —NR 2 , —S(O) 2 R, —S(O) 2 NR, —S(O)R, —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , or —N(R)S(O) 2 R;

each instance of R 9 is independently oxo, C 1-6 hydroxyaliphatic, —R 2 , halogen, —CN, —NO 2 , —OR, —SR, —NR 2 , —S(O) 2 R, —S(O) 2 NR 2 , —S(O)R, —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , or —N(R)S(O) 2 R;

m is 0-4;

n is 0-4;

p is 0-6; and

3. A method of treating a TYK2-mediated disorder disease, or condition in a patient wherein the disorder, disease, or condition is a hematological cancer, comprising administering to said patient a compound of formula I, or a pharmaceutical composition thereof;

or a pharmaceutically acceptable salt thereof, wherein:

each of X and Y is independently ═C(R 6 )— or ═N—, provided that X and Y are not simultaneously ═C(R 6 )—;

R 4 is hydrogen or optionally substituted C 1-6 aliphatic;

provided that when R 3 is other than phenyl, R 5 is not hydrogen or unsubstituted alkyl when L 1 is a covalent bond;

m is 0-4;

n is 0-4;

p is 0-6; and

4. The method of claim 3 wherein the hematological cancer is a leukemia.

5. The method of claim 4 , wherein the leukemia is a T-cell leukemia.

6. The method of claim wherein the T-cell leukemia is T-cell acute lymphoblastic leukemia (T-ALL).

7. A method of treating a TYK2-mediated disorder disease, or condition in a patient wherein the disorder, disease, or condition is associated with type I interferon, IL-10, IL-12, or IL-23 signaling, comprising administering to said patient a compound of formula I, or a pharmaceutical composition thereof:

or a pharmaceutically acceptable salt thereof, wherein:

each of X and Y is independently ═C(R 6 )— or ═N—, provided that X and Y are not simultaneously ═C(R 6 )—;

R 4 is hydrogen or optionally substituted C 1-6 aliphatic;

R 5 is a group selected from hydrogen, —R 2 , halogen, —CN, —NO 2 , —OR, —SR, —NR 2 , —S(O) 2 R, —S(O) 2 NR 2 , —S(O)R, —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , —N(R)S(O) 2 R, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R 5 is substituted with p instances of R 9 ;

provided that when R 3 is other than phenyl, R 5 is not hydrogen or unsubstituted alkyl when L 1 is a covalent bond;

m is 0-4;

n is 0-4;

p is 0-6; and